Literature DB >> 25077529

Effect of ranibizumab on high-speed indocyanine green angiography and minimum intensity projection optical coherence tomography findings in neovascular age-related macular degeneration.

Benjamin P Nicholson1, Divya Nigam, Brian Toy, Paul F Stetson, Elvira Agrón, Naima Jacobs-El, Denise Cunningham, Catherine Cukras, Wai Wong, Henry Wiley, Emily Chew, Frederick Ferris, Catherine B Meyerle.   

Abstract

PURPOSE: The purpose of this 1-year prospective study was to investigate how induction/pro re nata ranibizumab intravitreal treatment of eyes with neovascular age-related macular degeneration affects the anatomy of choroidal neovascularization (CNV) and the overlying outer retinal tissue.
METHODS: High-speed indocyanine green (HS-ICG) angiography measurements provided quantification of the CNV size in 60 patients followed for 1 year. Minimum intensity projection optical coherence tomography (MinIP OCT), a novel algorithm assessing minimum optical intensity between the internal limiting membrane and retinal pigment epithelium, measured the area of outer retinal disruption overlying the CNV. Fluorescein angiography was also assessed to evaluate late retinal leakage.
RESULTS: After 1 year, the mean area of CNV measured with indocyanine green angiography decreased by 5.8%. The mean area of MinIP OCT of outer retinal disruption overlying the CNV decreased by 4.2%. Mean area of fluorescein angiography leakage decreased by 6.3%. Both the area of outer retinal disruption measured with MinIP OCT and the area of leakage on fluorescein angiography typically exceeded the area of CNV on indocyanine green angiography at baseline and 1 year.
CONCLUSION: Choroidal neovascularization treated with induction/pro re nata intravitreal ranibizumab for 1 year essentially remained static. Minimum intensity projection optical coherence tomography suggests that the area of outer retinal disruption overlying the CNV may be greater than the CNV itself and often correlates with the leakage area on fluorescein angiography. Additionally, there was minimal change in the area of outer retinal disruption on MinIP OCT even when fluid resolved. Measurements of the extent of CNV lesions based on indocyanine green angiography and MinIP OCT may provide useful outcome variables to help assess the CNV complex longitudinally and warrant further validation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25077529      PMCID: PMC4276448          DOI: 10.1097/IAE.0000000000000260

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  15 in total

1.  Identification of well-defined intrachoroidal neovascularization by high-speed indocyanine green angiography.

Authors:  Sunil K Srivastava; Karl G Csaky
Journal:  Retina       Date:  2003-10       Impact factor: 4.256

2.  Anatomic response of occult choroidal neovascularization to intravitreal ranibizumab: a study by indocyanine green angiography.

Authors:  Giuseppe Querques; Thi Ha Chau Tran; Raimondo Forte; Lea Querques; Francesco Bandello; Eric H Souied
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-10-02       Impact factor: 3.117

3.  Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization.

Authors:  Nobuo Jo; Carolina Mailhos; Meihua Ju; Eunice Cheung; John Bradley; Kazuaki Nishijima; Gregory S Robinson; Anthony P Adamis; David T Shima
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

4.  Agreement between methods of measurement with multiple observations per individual.

Authors:  J Martin Bland; Douglas G Altman
Journal:  J Biopharm Stat       Date:  2007       Impact factor: 1.051

5.  Indocyanine green angiography of choroidal neovascular membranes.

Authors:  K Hayashi; J J de Laey
Journal:  Ophthalmologica       Date:  1985       Impact factor: 3.250

6.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

7.  Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

Authors:  Daniel F Martin; Maureen G Maguire; Stuart L Fine; Gui-shuang Ying; Glenn J Jaffe; Juan E Grunwald; Cynthia Toth; Maryann Redford; Frederick L Ferris
Journal:  Ophthalmology       Date:  2012-05-01       Impact factor: 12.079

8.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

Authors:  Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245

Review 9.  Emerging pharmacologic therapies for wet age-related macular degeneration.

Authors:  Zhang Ni; Peng Hui
Journal:  Ophthalmologica       Date:  2009-07-20       Impact factor: 3.250

10.  Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.

Authors:  David M Brown; Mark Michels; Peter K Kaiser; Jeffrey S Heier; Judy P Sy; Tsontcho Ianchulev
Journal:  Ophthalmology       Date:  2009-01       Impact factor: 12.079

View more
  1 in total

1.  Evolution of Geographic Atrophy in Participants Treated with Ranibizumab for Neovascular Age-related Macular Degeneration.

Authors:  Alisa T Thavikulwat; Naima Jacobs-El; Jane S Kim; Elvira Agrón; Jesia Hasan; Catherine B Meyerle; David Valent; Catherine A Cukras; Henry E Wiley; Wai T Wong; Emily Y Chew
Journal:  Ophthalmol Retina       Date:  2017 Jan-Feb
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.